Literature DB >> 24555864

Malignant pheochromocytoma in a 16-year-old patient with neurofibromatosis type 1.

Isabella Giovannoni1, Francesco Callea, Renata Boldrini, Alessandro Inserra, Raffaele Cozza, Paola Francalanci.   

Abstract

Patients with neurofibromatosis type I (NF1) feature a high risk of developing benign and malignant tumors, mainly those with a neuroectodermal origin, the risk being about 4 times higher than in the general population. Pheochromocytoma (PHEO) is a sporadic tumor (1∶100,000) arising from the adrenal medulla. Pheochromocytoma is a rare condition when occurring in conjunction with NF1 and occurs in about 1% of patients, rarely in those of pediatric age. In this study we present a 16-year-old patient with NF1 and malignant PHEO. Loss of heterozygosity analysis in PHEOs shows a reduction to homozygosity, observed for both 17p and 17q markers. This case confirms the importance of surveillance for malignant neoplasias in NF1 patients during childhood and adolescence. On the other hand, since 30% of PHEOs had germline mutations and, more rarely, somatic mutations, patients with PHEO should be investigated for associated genetic syndromes.

Entities:  

Keywords:  loss of heterozygosity; malignant pheochromocytoma; multicarcinoma syndromes; neurofibromatosis type 1

Mesh:

Year:  2014        PMID: 24555864     DOI: 10.2350/13-10-1397-CR.1

Source DB:  PubMed          Journal:  Pediatr Dev Pathol        ISSN: 1093-5266


  2 in total

1.  Phaeochromocytoma/paraganglioma and adverse clinical outcomes in patients with neurofibromatosis-1.

Authors:  Ahmed Al-Sharefi; Petros Perros; Robert Andrew James
Journal:  Endocr Connect       Date:  2018-08-17       Impact factor: 3.335

2.  Pediatric malignancies in neurofibromatosis type 1: A population-based cohort study.

Authors:  Sirkku Peltonen; Roope A Kallionpää; Matti Rantanen; Elina Uusitalo; Päivi M Lähteenmäki; Minna Pöyhönen; Janne Pitkäniemi; Juha Peltonen
Journal:  Int J Cancer       Date:  2019-02-18       Impact factor: 7.396

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.